Meyka Pro banner
IRIDEX Corporation

IRIDEX Corporation Fundamental Analysis (NASDAQ: IRIX)

IRIXNASDAQ
HealthcareMedical - Devices
$0.68
$0.005(0.72%)
U.S. Market opens in 3h 55m

IRIDEX Corporation Fundamental Analysis (NASDAQ: IRIX)

IRIDEX Corporation (NASDAQ: IRIX) shows moderate financial fundamentals with a PE ratio of -3.34, profit margin of -6.88%, and ROE of -78.94%. The company generates $0.1B in annual revenue with moderate year-over-year growth of 8.23%.

Key Strengths

Cash Position39.90%
PEG Ratio-0.07
Current Ratio1.82

Areas of Concern

ROE-78.94%
Operating Margin-5.39%
We analyze IRIX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -58.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-58.0/100

We analyze IRIX's fundamental strength across five key dimensions:

Efficiency Score

Weak

IRIX struggles to generate sufficient returns from assets.

ROA > 10%
-13.01%

Valuation Score

Excellent

IRIX trades at attractive valuation levels.

PE < 25
-3.34
PEG Ratio < 2
-0.07

Growth Score

Excellent

IRIX delivers strong and consistent growth momentum.

Revenue Growth > 5%
8.23%
EPS Growth > 10%
51.85%

Financial Health Score

Moderate

IRIX shows balanced financial health with some risks.

Debt/Equity < 1
1.10
Current Ratio > 1
1.82

Profitability Score

Weak

IRIX struggles to sustain strong margins.

ROE > 15%
-7893.62%
Net Margin ≥ 15%
-6.88%
Positive Free Cash Flow
No

Key Financial Metrics

Is IRIX Expensive or Cheap?

P/E Ratio

IRIX trades at -3.34 times earnings. This suggests potential undervaluation.

-3.34

PEG Ratio

When adjusting for growth, IRIX's PEG of -0.07 indicates potential undervaluation.

-0.07

Price to Book

The market values IRIDEX Corporation at 3.25 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.25

EV/EBITDA

Enterprise value stands at -7.29 times EBITDA. This is generally considered low.

-7.29

How Well Does IRIX Make Money?

Net Profit Margin

For every $100 in sales, IRIDEX Corporation keeps $-6.88 as profit after all expenses.

-6.88%

Operating Margin

Core operations generate -5.39 in profit for every $100 in revenue, before interest and taxes.

-5.39%

ROE

Management delivers $-78.94 in profit for every $100 of shareholder equity.

-78.94%

ROA

IRIDEX Corporation generates $-13.01 in profit for every $100 in assets, demonstrating efficient asset deployment.

-13.01%

Following the Money - Real Cash Generation

Operating Cash Flow

IRIDEX Corporation generates limited operating cash flow of $-1.72M, signaling weaker underlying cash strength.

$-1.72M

Free Cash Flow

IRIDEX Corporation generates weak or negative free cash flow of $-1.76M, restricting financial flexibility.

$-1.76M

FCF Per Share

Each share generates $-0.10 in free cash annually.

$-0.10

FCF Yield

IRIX converts -15.22% of its market value into free cash.

-15.22%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.34

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.25

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.23

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.82

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.79

vs 25 benchmark

ROA

Return on assets percentage

-0.13

vs 25 benchmark

ROCE

Return on capital employed

-0.20

vs 25 benchmark

How IRIX Stacks Against Its Sector Peers

MetricIRIX ValueSector AveragePerformance
P/E Ratio-3.3431.00 Better (Cheaper)
ROE-78.94%524.00% Weak
Net Margin-6.88%21528.00% Weak
Debt/Equity1.100.53 Weak (High Leverage)
Current Ratio1.825.64 Neutral
ROA-13.01%-104.00% (disorted) Weak

IRIX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews IRIDEX Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

16.72%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

43.54%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

47.38%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ